UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) of the

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of of earliest event reported): ~~June~~May 3010, ~~2006~~2007

BRADLEY PHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction of incorporation)

0-31680
(Commission File Number)

22-2581418
(IRS Employer Identification No.)

383 Route 46 West, Fairfield, New Jersey
(Address of principal executive offices)

07004
(Zip Code)

Registrant’s telephone number, including area code: (973) 882-1505

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

|_|

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

|_|

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

|_|

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

|_|

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 82.~~01.~~02 ~~Other~~ Results ~~Events~~of Operations and Financial Condition.

On May ~~June 30~~10, ~~2006~~2007, Bradley Pharmaceuticals, Inc. (the “Company”) issued a press release announcing itits ~~has~~financial ~~been~~results ~~advised~~for bythe ~~MediGene AG~~first ~~(Frankfurt,~~quarter ~~TecDAX:~~ended ~~MDG),~~March ~~its licensor of Polyphenon® E Ointment~~31, ~~that~~2007. A ~~the~~copy ~~FDA has~~of ~~extended~~ the ~~deadline~~Company’s ~~for~~press ~~the~~release ~~completion~~is ofattached ~~its~~as ~~review~~Exhibit of99.1 to this ~~product~~Current ~~for~~Report ~~treatment~~on ofForm ~~external~~8-K, ~~genital~~and ~~warts~~is toincorporated ~~October~~by ~~31,~~reference ~~2006~~into this Item 2.02.

A The information ~~copy~~in of this ~~press~~Item ~~release~~2.02 ~~is being~~of ~~filed~~Form as8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to ~~this~~the ~~Form~~liabilities ~~8-K~~of ~~and~~that issection, ~~incorporated~~nor ~~herein~~shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or ~~its~~the ~~entirety~~Exchange Act.

Item 9.01. Financial Statements and Exhibits.

(dc) Exhibits.

No. Description

Number		Description
99.1		Press Release dated May 10, 2007

99.1 Press release dated June 30, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BRADLEY PHARMACEUTICALS, INC. By: /s/ ~~Daniel~~R. ~~Glassman~~Brent ~~Chairman~~Lenczycki ofR. ~~the~~Brent ~~Board~~Lenczycki, ~~President~~CPA ~~and~~ Chief ~~Executive~~Financial Officer and Vice President

Dated: ~~June~~May 3011, ~~2006~~2007

EXHIBIT INDEX

Number		Description
99.1		Press Release dated May 10, 2007

Filing Compare · BRADLEY PHARMACEUTICALS INC